Chemistry World: Treating our brains better

Major pharmaceutical companies have long been downsizing their central nervous system (CNS) research and development programmes. Between 2009 and 2014, there was a 52% drop in CNS drug discovery and development programmes pursued by large pharma, with almost all companies showing a decline. That situation has continued, despite great unmet needs remaining in mental health and other CNS conditions…

Powered by GlobalLink OneLink Software